Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation

被引:36
作者
Brown, JH
Murphy, BG
Douglas, AF
Short, CD
Bhatnagar, D
Mackness, MI
Hunt, LP
Doherty, CC
Durrington, PN
机构
[1] UNIV MANCHESTER, DEPT MED, RENAL UNIT, MANCHESTER M13 9PL, LANCS, ENGLAND
[2] MANCHESTER ROYAL INFIRM, FAC MED, COMPUTAT GRP, MANCHESTER M13 9WL, LANCS, ENGLAND
[3] BELFAST CITY HOSP, REG NEPHROL UNIT, BELFAST BT9 7AD, ANTRIM, NORTH IRELAND
关键词
cyclosporin; immunosuppression; lipids; lipoprotein(a); renal transplantation;
D O I
10.1159/000189549
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Coronary heart disease (CHD) is more common in patients with chronic renal failure and is a major cause of death after renal transplantation. Elevated serum levels of lipoprotein(a) (Lp(a)) are a known risk factor for CHD in the general population and levels have been reported to be increased in renal transplant recipients. It has been suggested that cyclosporin may elevate Lp(a) levels. We therefore measured the serum concentration of Lp(a) in 50 renal transplant recipients who were receiving cyclosporin alone as immunosuppressive therapy and 50 who were treated with azathioprine and prednisolone, but not cyclosporin. The patients attended two renal transplant centres, one where cyclosporin alone was used as immunosuppressive treatment when possible and another where many patients commenced on azathioprine and prednisolone remain on this medication rather than cyclosporin. Patients in each group were matched for age and sex, but the time since transplantation was greater in those not receiving cyclosporin. Transplant function, obesity and the underlying cause of renal disease were similar in both groups of patients. Median Lp(a) concentration in the cyclosporin monotherapy group was 32.0 (range <0.8-140.3) mg/dl and was significantly (p < 0.05) greater than that of the azathioprine and prednisolone group which was 18.3 (range <0.8-167.7) mg/dl. The serum high-density lipoprotein (HDL) cholesterol concentration, which was 1.24 +/- 0.39 mmol/l (mean +/- SD) in patients receiving cyclosporin, was significantly (p < 0.05) less than that of those treated with azathioprine and prednisolone in whom it was 1.41 +/- 0.40 mmol/l. The lower level in those on cyclosporin was due to a decrease in the HDL(2) subfraction. Serum lipid and lipoprotein concentrations were otherwise similar in the two groups of patients. The serum level of Lp(a) after renal transplantation may be influenced by the choice of immunosuppressive therapy.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 34 条
  • [1] ADOLPHSON JL, 1989, J LIPID RES, V30, P597
  • [2] CYCLOSPORINE-A HAS DIVERGENT EFFECTS ON PLASMA LDL CHOLESTEROL (LDL-C) AND LIPOPROTEIN(A) [LP(A)] LEVELS IN RENAL-TRANSPLANT RECIPIENTS - EVIDENCE FOR RENAL INVOLVEMENT IN THE MAINTENANCE OF LDL-C AND THE ELEVATION OF LP(A) CONCENTRATIONS IN HEMODIALYSIS-PATIENTS
    AZROLAN, N
    BROWN, CD
    THOMAS, L
    HAYEK, T
    ZHAO, ZH
    ROBERTS, KG
    SCHEINER, C
    FRIEDMAN, EA
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (09): : 1393 - 1398
  • [3] LIPOPROTEIN(A) AND ACCELERATED CORONARY-ARTERY DISEASE IN CARDIAC TRANSPLANT RECIPIENTS
    BARBIR, M
    KUSHWAHA, S
    HUNT, B
    MACKEN, A
    THOMPSON, GR
    MITCHELL, A
    ROBINSON, D
    YACOUB, M
    [J]. LANCET, 1992, 340 (8834-5) : 1500 - 1502
  • [4] BHATNAGAR D, 1995, LANCET, V345, P405
  • [5] BLACK IW, 1992, CLIN CHEM, V38, P353
  • [6] BROWN JH, 1993, NEPHROL DIAL TRANSPL, V8, P863
  • [7] COMPARATIVE MORTALITY FROM CARDIOVASCULAR-DISEASE IN PATIENTS WITH CHRONIC-RENAL-FAILURE
    BROWN, JH
    HUNT, LP
    VITES, NP
    SHORT, CD
    GOKAL, R
    MALLICK, NP
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1994, 9 (08) : 1136 - 1142
  • [8] LIPOPROTEIN LP(A) AS PREDICTOR OF MYOCARDIAL-INFARCTION IN COMPARISON TO FIBRINOGEN - LDL CHOLESTEROL AND OTHER RISK-FACTORS - RESULTS FROM THE PROSPECTIVE GOTTINGEN RISK INCIDENCE AND PREVALENCE STUDY (GRIPS)
    CREMER, P
    NAGEL, D
    LABROT, B
    MANN, H
    MUCHE, R
    ELSTER, H
    SEIDEL, D
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1994, 24 (07) : 444 - 453
  • [9] DURRINGTON PN, 1988, LANCET, V1, P1070
  • [10] EDWARDS BD, 1995, QJM-MON J ASSOC PHYS, V88, P109